FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
(NASDAQ: ARQT) Delayed: 25.38 -1.08 (4.08%)
Previous Close $26.46    52 Week High $ 
Open $26.14    52 Week Low $ 
Day High $26.75    P/E N/A 
Day Low $25.13    EPS $ 
Volume 19,137,078